Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use

Journal of Immunological Methods

Volumn 384, Issue 1-2, 2012, Pages 92-102

  Pepys, Mark B ^a   Gallimore, J Ruth ^a   Lloyd, Joanne ^b   Li, Zhanhong ^b   Graham, David ^c   Taylor, Graham W ^a   Ellmerich, Stephan ^a   Mangione, Palma P ^a,d   Tennent, Glenys A ^a   Hutchinson, Winston L ^a   Millar, David J ^a   Bennett, Gary ^e   More, John ^b   Evans, David ^b   Mistry, Yogesh ^f   Poole, Stephen ^f   Hawkins, Philip N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BIO PRODUCTS LABORATORY   (United Kingdom)

^c SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^d UNIVERSITY OF PAVIA   (Italy)

^e ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^f NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

C reactive protein; Cytokine; Good manufacturing practice; Mononuclear cells; Pharmaceutical; Serum amyloid P component

Indexed keywords

ALPHA (3,4 DIMETHOXYBENZYLIDENE) 2 PYRIDYLACETONITRILE; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PENTRAXIN; RECOMBINANT PROTEIN; SERUM AMYLOID P; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; CYTOKINE RELEASE; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN PURIFICATION; PROTEIN STRUCTURE;

ACUTE-PHASE PROTEINS; AMYLOIDOSIS; ANIMALS; C-REACTIVE PROTEIN; CELLS, CULTURED; CHROMATOGRAPHY, GEL; CYTOKINES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED C57BL; SERUM AMYLOID P-COMPONENT; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 84865606784     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.07.013     Document Type: Article

References (72)

1. Ballou S.P., Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992, 4:361.
2. Baltz M.L., Rowe I.F., Pepys M.B. In vivo studies of the clearance of C-reactive protein. Clin. Exp. Immunol. 1985, 59:243.
3. Bickerstaff M.C.M., Botto M., Hutchinson W.L., Herbert J., Tennent G.A., Bybee A., Mitchell D.A., Cook H.T., Butler P.J.G., Walport M.J., Pepys M.B. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat. Med. 1999, 5:694.
4. Bisoendial R.J., Kastelein J.J.P., Levels J.H.M., Zwaginga J.J., van den Bogaard B., Reitsma P.H., Meijers J.C.M., Hartman D., Levi M., Stroes E.S.G. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ. Res. 2005, 96:714.
5. Bisoendial R.J., Kastelein J.J.P., Peters S.L.M., Levels J.H.M., Birjmohun R., Rotmans J.I., Hartman D., Meijers J.C.M., Levi M., Stroes E.S.G. Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J. Lipid Res. 2007, 48:952.
6. Bisoendial R.J., Kastelein J.J.P., Stroes E.S.G. C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis 2007, 195:e10.
7. Bisoendial R.J., Birjmohun R.S., Akdim F., van't Veer C., Spek C.A., Hartman D., de Groot E.R., Bankaitis-Davis D.M., Kastelein J.J.P., Stroes E.S.G. C-reactive protein elicits white blood cell activation in humans. Am. J. Med. 2009, 122:582.e1.
8. Bodin K., Ellmerich S., Kahan M.C., Tennent G.A., Loesch A., Gilbertson J.A., Hutchinson W.L., Mangione P.P., Gallimore J.R., Millar D.J., Minogue S., Dhillon A.P., Taylor G.W., Bradwell A.R., Petrie A., Gillmore J.D., Bellotti V., Botto M., Hawkins P.N., Pepys M.B. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010, 468:93.
9. Botto M., Hawkins P.N., Bickerstaff M.C.M., Herbert J., Bygrave A.E., McBride A., Hutchinson W.L., Tennent G.A., Walport M.J., Pepys M.B. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat. Med. 1997, 3:855.
10. Butler P.J.G., Tennent G.A., Pepys M.B. Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin. J. Exp. Med. 1990, 172:13.
11. Wensley F., Gao P., Burgess S., Kaptoge S., Di Angelantonio E., Shah T., Engert J.C., Clarke R., Davey-Smith G., Nordestgaard B.G., Saleheen D., Samani N.J., Sandhu M., Anand S., Pepys M.B., Smeeth L., Whittaker J., Casas J.P., Thompson S.G., Hingorani A.D., Danesh J. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011, 342:d548. C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC).
12. Carlucci F., Cook H.T., Garg A., Pepys M.B., Botto M. Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis. Arthritis Rheum. 2010, 62:245.
13. 131I-serum amyloid P component. Arthritis Rheum. 1987, 30:1303.
14. Castaño A.P., Lin S.-L., Surowy T., Nowlin B.T., Turlapati S.A., Patel T., Singh A., Li S., Lupher M.L., Duffield J.S. Serum amyloid P inhibits fibrosis through FcγR-dependent monocyte-macrophage regulation in vivo. Sci. Transl. Med. 2009, 1:5ra13.
15. de Beer F.C., Pepys M.B. Isolation of human C-reactive protein and serum amyloid P component. J. Immunol. Methods 1982, 50:17.
16. de Beer F.C., Baltz M.L., Munn E.A., Feinstein A., Taylor J., Bruton C., Clamp J.R., Pepys M.B. Isolation and characterisation of C-reactive protein and serum amyloid P component in the rat. Immunology 1982, 45:55.
17. de Maat M.P.M., Trion A. C-reactive protein as a risk factor versus risk marker. Curr. Opin. Lipidol. 2004, 15:651.
18. Eda S., Kaufmann J., Roos W., Pohl S. Development of a new microparticle-enhanced turbidometric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J. Clin. Lab. Anal. 1998, 12:137.
19. Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., Collins R., Danesh J., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132. Emerging Risk Factors Collaboration.
20. Erlandsen E.J., Randers E. Reference interval for serum C-reactive protein in healthy blood donors using the Dade Behring N latex mono assay. Scand. J. Clin. Lab. Invest. 2000, 60:37.
21. Findlay L., Eastwood D., Stebbings R., Sharp G., Mistry Y., Ball C., Hood J., Thorpe R., Poole S. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J. Immunol. Methods 2010, 352:1.
22. Gaines Das R.E., Brügger P., Patel M., Mistry Y., Poole S. Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: test design and data analysis. J. Immunol. Methods 2004, 288:165.
23. Gillmore J.D., Hutchinson W.L., Herbert J., Bybee A., Mitchell D.A., Hasserjian R.P., Yamamura K., Suzuki M., Sabin C.A., Pepys M.B. Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?. Immunology 2004, 112:255.
24. Gillmore J.D., Tennent G.A., Hutchinson W.L., Gallimore J.R., Lachmann H.J., Goodman H.J.B., Offer M., Millar D.J., Petrie A., Hawkins P.N., Pepys M.B. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br. J. Haematol. 2010, 148:760.
25. Haudek S.B., Xia Y., Huebener P., Lee J.M., Carlson S., Crawford J.R., Pilling D., Gomer R.H., Trial J., Frangogiannis N.G., Entman M.L. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18284.
26. Hawkins P.N. Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clin. Sci. 1994, 87:289.
27. 123I-labeled serum amyloid P component. J. Exp. Med. 1988, 167:903.
28. Hawkins P.N., Myers M.J., Lavender J.P., Pepys M.B. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet 1988, i:1413.
29. 123I-labeled serum amyloid P component. N. Engl. J. Med. 1990, 323:508.
30. Hawkins P.N., Wootton R., Pepys M.B. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J. Clin. Invest. 1990, 86:1862.
31. Hawkins P.N., Tennent G.A., Woo P., Pepys M.B. Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis. Clin. Exp. Immunol. 1991, 84:308.
32. Hawkins P.N., Richardson S., MacSweeney J.E., King A.D., Vigushin D.M., Lavender J.P., Pepys M.B. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. Q. J. Med. 1993, 86:365.
33. Hawkins P.N., Richardson S., Vigushin D.M., David J., Kelsey C.R., Gray R.E.S., Hall M.A., Woo P., Lavender J.P., Pepys M.B. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. Arthritis Rheum. 1993, 36:842.
34. Hirschfield G.M., Gallimore R., Gilbertson J.A., Benson M., Pepys M.B. Systemic inflammation and atherogenesis in apoE knockout mice expressing transgenic human C-reactive protein. Circulation 2003, 108(Suppl. IV):IV-41. (abstract).
35. Hirschfield G.M., Gallimore J.R., Kahan M.C., Hutchinson W.L., Sabin C.A., Benson G.M., Dhillon A.P., Tennent G.A., Pepys M.B. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8309.
36. Holmgren G., Ericzon B.-G., Groth C.-G., Steen L., Suhr O., Andersen O., Wallin B.G., Seymour A., Richardson S., Hawkins P.N., Pepys M.B. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993, 341:1113.
37. Kistler P., Nitschmann H. Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang. 1962, 7:414.
38. Koike T., Kitajima S., Yu Y., Nishijima K., Zhang J., Ozaki Y., Morimoto M., Watanabe T., Bhakdi S., Asada Y., Chen Y.E., Fan J. Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation 2009, 120:2088.
39. Kolstoe S.E., Ridha B.H., Bellotti V., Wang N., Robinson C.V., Crutch S.J., Keir G., Kukkastenvehmas R., Gallimore J.R., Hutchinson W.L., Hawkins P.N., Wood S.P., Rossor M.N., Pepys M.B. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7619.
40. Kovacs A., Tornvall P., Nilsson R., Tegnér J., Hamsten A., Björkegren J. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13768.
41. Labarrere C.A., Zaloga G.P. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am. J. Med. 2004, 117:499.
42. Loeffler J.M., Simons J.P., Al-Shawi R.A., Hutchinson W.L., Mangione P., Pepys M.B. C-reactive protein is essential for host resistance to pneumococci. Q. J. Med. 2009, 102:644. (abstract).
43. Nelson S.R., Tennent G.A., Sethi D., Gower P.E., Ballardie F.W., Amatayakul-Chantler S., Pepys M.B. Serum amyloid P component in chronic renal failure and dialysis. Clin. Chim. Acta 1991, 200:191.
44. Noursadeghi M., Bickerstaff M.C.M., Gallimore J.R., Herbert J., Cohen J., Pepys M.B. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:14584.
45. Oliveira E.B., Gotschlich E.C., Liu T.-Y. Primary structure of human C-reactive protein. J. Biol. Chem. 1979, 254:489.
46. Pepys M.B. Isolation of serum amyloid P component (protein SAP) in the mouse. Immunology 1979, 37:637.
47. Pepys M.B. CRP or not CRP? That is the question. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1091.
48. Pepys M.B. Amyloidosis. Annu. Rev. Med. 2006, 57:223.
49. Pepys M.B., Baltz M.L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv. Immunol. 1983, 34:141.
50. Pepys M.B., Butler P.J.G. Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Biochem. Biophys. Res. Commun. 1987, 148:308.
51. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J. Clin. Invest. 2003, 111:1805.
52. Pepys M.B., Baltz M., Gomer K., Davies A.J.S., Doenhoff M. Serum amyloid P-component is an acute-phase reactant in the mouse. Nature 1979, 278:259.
53. Pepys M.B., Dyck R.F., de Beer F.C., Skinner M., Cohen A.S. Binding of serum amyloid P component (SAP) by amyloid fibrils. Clin. Exp. Immunol. 1979, 38:284.
54. Pepys M.B., Rademacher T.W., Amatayakul-Chantler S., Williams P., Noble G.E., Hutchinson W.L., Hawkins P.N., Nelson S.R., Gallimore J.R., Herbert J., Hutton T., Dwek R.A. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:5602.
55. Pepys M.B., Booth D.R., Hutchinson W.L., Gallimore J.R., Collins P.M., Hohenester E. Amyloid P component. A critical review. Amyloid: Int. J. Exp. Clin. Invest. 1997, 4:274.
56. Pepys M.B., Herbert J., Hutchinson W.L., Tennent G.A., Lachmann H.J., Gallimore J.R., Lovat L.B., Bartfai T., Alanine A., Hertel C., Hoffmann T., Jakob-Roetne R., Norcross R.D., Kemp J.A., Yamamura K., Suzuki M., Taylor G.W., Murray S., Thompson D., Purvis A., Kolstoe S., Wood S.P., Hawkins P.N. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002, 417:254.
57. Pepys M.B., Hawkins P.N., Kahan M.C., Tennent G.A., Gallimore J.R., Graham D., Sabin C.A., Zychlinsky A., de Diego J. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ. Res. 2005, 97:e97.
58. Pepys M.B., Hirschfield G.M., Tennent G.A., Gallimore J.R., Kahan M.C., Bellotti V., Hawkins P.N., Myers R.M., Smith M.D., Polara A., Cobb A.J.A., Ley S.V., Aquilina J.A., Robinson C.V., Sharif I., Gray G.A., Sabin C.A., Jenvey M.C., Kolstoe S.E., Thompson D., Wood S.P. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006, 440:1217.
59. Pepys M.B., Tennent G.A., Denton C.P. Reply to Letter from Pilling, D., Buckley, C.D., Salmon, M. and Gomer, R.G., Serum amyloid P and fibrosis in systemic sclerosis: comment on the article by Tennent et al. Arthritis Rheum. 2007, 56:4229.
60. Pilling D., Buckley C.D., Salmon M., Gomer R.H. Inhibition of fibrocyte differentiation by serum amyloid P. J. Immunol. 2003, 171:5537.
61. Pontet M., Engler R., Jayle M.F. One step preparation of both human C-reactive protein and C1t. FEBS Lett. 1978, 88:172.
62. Poole S., Gordon A.H., Baltz M., Stenning B.E. Effect of bacterial endotoxin on body temperature, plasma zinc and plasma concentrations of the acute-phase protein serum amyloid P component in mice. Br. J. Exp. Pathol. 1984, 65:431.
63. Poole S., Gaines Das R.E., Baltz M., Pepys M.B. Detection of endotoxin in mice by measurement of endotoxin-induced changes in plasma concentrations of zinc and of the acute-phase protein serum amyloid P component. J. Pharm. Pharmacol. 1986, 38:807.
64. Poole S., Mistry Y., Ball C., Gaines Das R.E., Opie L.P., Tucker G., Patel M. A rapid 'one-plate' in vitro test for pyrogens. J. Immunol. Methods 2003, 274:209.
65. Shine B., de Beer F.C., Pepys M.B. Solid phase radioimmunoassays for human C-reactive protein. Clin. Chim. Acta 1981, 117:13.
66. Tanaka T., Horio T., Matuo Y. Secretory production of recombinant human C-reactive protein in Escherichia coli, capable of binding with phosphorylcholine, and its characterization. Biochem. Biophys. Res. Commun. 2002, 295:163.
67. Taylor K.E., van den Berg C.W. Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein. Immunology 2007, 120:404.
68. Taylor K.E., Giddings J.C., van den Berg C.W. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1225.
69. Tennent G.A., Dziadzio M., Triantafillidou E., Davies P., Gallimore J.R., Denton C.P., Pepys M.B. Normal circulating serum amyloid P component concentration in systemic sclerosis. Arthritis Rheum. 2007, 56:2013.
70. -/- mice. Atherosclerosis 2008, 196:248.
71. Teupser D., Weber O., Rao T.N., Sass K., Thiery J., Fehling H.J. No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J. Biol. Chem. 2011, 286:6272.
72. Vigushin D.M., Pepys M.B., Hawkins P.N. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J. Clin. Invest. 1993, 91:1351.